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Abstract
Objective The current article encompasses a literature review and recommendations for radiotherapy in nodal oligorecur-
rent prostate cancer.
Materials and methods A literature review focused on studies comparing metastasis-directed stereotactic ablative radio-
therapy (SABR) vs. external elective nodal radiotherapy (ENRT) and studies analyzing recurrence patterns after local
nodal treatment was performed. The DEGRO Prostate Cancer Expert Panel discussed the results and developed treatment
recommendations.
Results Metastasis-directed radiotherapy results in high local control (often >90% within a follow-up of 1–2 years) and
can be used to improve progression-free survival or defer androgen deprivation therapy (ADT) according to prospective
randomized phase II data. Distant progression after involved-node SABR only occurs within a few months in the majority
of patients. ENRT improves metastases-free survival rates with increased toxicity in comparison to SABR according to
retrospective comparative studies. The majority of nodal recurrences after initial local treatment of pelvic nodal metastasis
are detected within the true pelvis and common iliac vessels.
Conclusion ENRT with or without a boost should be preferred to SABR in pelvic nodal recurrences. In oligometastatic
prostate cancer with distant (extrapelvic) nodal recurrences, SABR alone can be performed in selected cases. Application of
additional systemic treatments should be based on current guidelines, with ADT as first-line treatment for hormone-sensitive
prostate cancer. Only in carefully selected patients can radiotherapy be initially used without additional ADT outside of the
current standard recommendations. Results of (randomized) prospective studies are needed for definitive recommendations.
For the Prostate Cancer Expert Panel of the German Society of
Radiation Oncology (DEGRO) and the Radiation Oncology
Working Group of the German Cancer Society (DKG-ARO)
 Prof. Dr. med. Michael Pinkawa
michael.pinkawa@post.rwth-aachen.de
1 Department of Radiation Oncology, MediClin Robert Janker
Klinik, Bonn, Germany
2 Department of Radiation Oncology, Universitätsklinikum
RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Germany
3 Department of Radiation Oncology, Inselspital, University of
Bern, Bern, Switzerland
4 Department of Radiation Oncology, Charité
Universitätsmedizin Berlin, Berlin, Germany
5 Department of Radiation Oncology, Universitätsklinikum
Würzburg, Würzburg, Germany
6 Department of Radiation Oncology, University Hospital,
LMU Munich, Munich, Germany
7 Xcare Praxis für Strahlentherapie Saarlouis, Xcare Gruppe,
Saarlouis, Germany
8 Department of Radiotherapy and Radiation Oncology,
University Hospital Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany
9 Department of Radiation Oncology, Eberhard Karls
University, Tübingen, Germany
10 Department of Radiation Oncology, Sana Klinikum
Offenbach, Offenbach, Germany
11 Landeskrankenhaus, Universitätsklinikum der Paracelsus
Medizinischen Privatuniversität Salzburg, Salzburg, Austria
12 Department of Radiation Oncology, Universitätsklinikum
Freiburg, Freiburg, Germany




Keywords Prostate cancer · Oligorecurrence · Metastasis-directed therapy · Radiation therapy · Androgen deprivation
therapy · Stereotactic body radiotherapy · Oligmometastases · Lymph node metastases
Introduction
Recent advances in diagnostic techniques as well as lo-
cal and systemic treatments have improved outcomes in
prostate cancer (PCa) patients [1–3]. Diagnostic procedures
increasingly include magnetic resonance imaging (MRI)
and positron-emission tomography/computed tomography
(PET/CT), currently above all using prostate-specific mem-
brane antigen (PSMA) for improved local and systemic
staging [4]. Thus, relapses can already be detected with
low prostate-specific antigen (PSA) levels, which frequently
lead to the diagnosis of oligorecurrence in a small num-
ber of lymph nodes after local prostate treatment (radical
prostatectomy or radiotherapy) [5]. So far, it is not known
if identification and treatment of low-volume nodal recur-
rences improves the survival of these patients.
Following primary treatment, 20–50% of high-risk pa-
tients develop biochemical recurrences [6, 7]. Generally,
patients with low-volume disease are known to have a better
outcome than patients with high-volume disease [8]. Com-
monly, androgen deprivation therapy (ADT) is initiated in
recurrent disease. However, local treatment as the sole in-
tervention or in combination with ADT is increasingly used
[7].
This is similar to intensification of treatment in non-
small cell lung cancer. Two randomized phase II trials
in oligometastatic non-small cell lung cancer showed im-
proved progression-free and overall survival after stereo-
tactic ablative radiotherapy (SABR) was added to mainte-
nance systemic therapy [9, 10]. The SABR-COMET (Com-
prehensive Treatment of Oligometastases) trial reported an
overall survival benefit when SABR was used in addition
to standard-of-care systemic therapy across various histolo-
gies (including 16 prostate cancer patients) [11, 12].
With radiotherapy being increasingly applied in oligore-
current and oligometastatic prostate cancer, the aim of this
manuscript is to define the role of radiotherapy in nodal
oligorecurrent PCa.
Materials andmethods
A review of the literature was performed. The analysis fo-
cused on studies analyzing recurrence patterns after local
nodal treatment and studies comparing SABR for nodal
recurrences vs. observation, or SABR (synonymous with
stereotactic body radiotherapy, SBRT, or involved-field ra-
diotherapy, IFRT) for nodal recurrences vs. elective nodal
radiotherapy (ENRT). The Prostate Cancer Expert Panel of
the German Society of Radiation Oncology (DEGRO) dis-
cussed the results and developed treatment recommenda-
tions on the radiotherapy volume, radiotherapy technique,
and role of additional systemic therapy.
Results
Comparison of different local nodal treatments or
observation
Two prospective, randomized, multicenter phase II tri-
als were recently published in recurrent prostate can-
cer, comparing surveillance or metastasis-directed therapy
(MDT) [13, 14]. In the STOMP (Surveillance or MDT for
Oligometastatic Prostate Cancer Recurrence) trial, patients
(n= 62) with up to three PET-positive metastatic lesions,
including 55% lymph node (LN) metastasis in both groups,
were included. MDT included SABR (30Gy in three frac-
tions) in most patients (n= 25), but also surgery (n= 6). At
a median follow-up of 3 years, the median ADT-free sur-
vival (primary endpoint) was 13 months in the surveillance
group and 21 months in the MDT group (hazard ratio, HR:
0.6; p= 0.11). In the intention-to-treat analysis, a signifi-
cant difference was only found for nodal metastases (HR
0.4 for nodal, p= 0.04 vs. HR 0.75, p= 0.51 for non-nodal
metastases) [13].
The ORIOLE (Observation vs. Stereotactic Ablative
Radiation for Oligometastatic Prostate Cancer) trial also
included patients (n= 54) with up to three metastatic le-
sions in conventional imaging, randomized 2:1 to SABR
(19.5–48Gy in 3–5 fractions) or observation. In 61%,
metastatic lesions included only lymph nodes. Biochemical
or clinical progression at 6 months occurred in 19% of
patients receiving SABR and 61% undergoing observation
(p< 0.01). Total regression of PSMA radiotracer-avid dis-
ease decreased the risk of new lesions at 6 months (16 vs.
63%; p< 0.01). SABR was suggested to induce a systemic
immune response. The presence of high-risk mutations in
circulating tumor DNA (ctDNA, detectable in 22 patients)
might be associated with a worse prognosis [14].
Larger patient numbers with a longer follow-up were
evaluated in a multi-institutional retrospective case–control
study for PET-detected nodal oligorecurrent prostate can-
cer (90% limited to the pelvis). In the MDT cohort, 166 pa-
tients received salvage lymph node resection and 97 patients
SABR. The standard-of-care cohort included 1816 patients
and was matched 3:1 with the MDT cohort. After a me-
dian follow-up of 70 months, a significant cancer-specific
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survival benefit resulted for patients after MDT (98.6 vs.
95.7% 5-year survival, p< 0.01) [15].
A multi-institutional retrospective study (15 different
centers) compared SABR vs. ENRT. This analysis in-
cluded 506 patients (SABR: 309; ENRT: 197) patients
with hormone-sensitive oligorecurrent PCa defined by up
to five lymph node (LN) metastases in pelvic (N1: 365) or
extrapelvic (M1a: 98) nodes (N1 combined with M1a: 43).
The median follow-up was 36 months (interquartile range
23–56 months). SABR was defined as a minimum of 5Gy
per fraction with a maximum of 10 fractions. ENRT was
defined as a minimum dose of 45Gy in up to 25 fractions
to the elective nodes (without specific definition), with or
without a simultaneous integrated boost to the suspicious
node(s). Nodal recurrences were detected by PET/CT in
97% (choline: n= 428; PSMA: n= 46; fluorodeoxyglucose:
n= 17) or conventional imaging in 3% (MRI: n= 5; CT:
n= 10) of cases. The 3-year metastasis-free survival was
68% for SABR and 77% for ENRT (p= 0.01). Overall,
ENRT was associated with significantly fewer nodal re-
currences compared to SABR (20 vs. 42%; p< 0.001),
especially with fewer pelvic recurrences (2 vs. 18%). In
multivariate analysis, patients with a single LN recurrence
had longer metastasis-free survival after ENRT (hazard
ratio: 0.5; p= 0.009). Late toxicity was higher after ENRT
compared to SABR (18 vs. 6%, p< 0.01, including 2.5%
vs. 0 grade 3 or 4 toxicity). Limitations of this retrospective
study include higher use of ADT (applied at the discre-
tion of the treating physician) in the ENRT cohort and
nonstandardized follow-up [16].
In a further, overall smaller retrospective study compar-
ing ENRT (including a boost to the involved nodes) with
SABR, 62 patients were included. A 3-year failure-free sur-
vival of 88 vs. 55% (p< 0.001) was reported by Lépinoy
et al. [17]. In contrast to the multi-institutional study, ENRT
was well defined in this study. ENRT included the whole
pelvis as defined by the radiation therapy oncology group
(RTOG; [18]). In patients with PET-positive common iliac
or lower paraaortic lymph nodes, the clinical target vol-
ume (CTV) was extended up to the L2/L3 space. When
lumboaortic lymph nodes were involved, the CTV was ex-
tended up to the renal arteries.
Recurrence patterns after local nodal treatment
In an analysis of 72 patients after SABR for up to three LN
recurrences (overall 89 LN; N1/M1a), 68% relapses oc-
curred again in nodal regions. Relapses after pelvic nodal
SABR (n= 36) were located in the pelvis (39%), retroperi-
toneum (3%), pelvis and retroperitoneum (22%), or in non-
nodal regions (36%) [19].
De Bruycker et al. evaluated 158 LN recurrences in
82 patients with up to five LN (N1/M1a) after primary lym-
phadenectomy (n= 12) or ENRT (n= 12) or combined lym-
phadenectomy with ENRT (n= 56; missing information in
2 patients). In 49% of patients, recurrences were exclusively
located in the true pelvis, followed by the common iliac
LN (10%), retroperitoneal/inguinal LN (10%), or a com-
bination (31%). In contrast to ENRT, limited or standard
LN dissection was considered insufficient as a salvage ap-
proach. Limiting the upper border to the top of L4 instead
of L5/S1 would increase lesion coverage from 43 to 67%
[20].
Soldatov et al. analyzed recurrence patterns in 108 pa-
tients after 68Ga-prostate specific membrane antigen (PSMA)
ligand PET/CT-guided RT (without additional systemic
treatment) for recurrent oligometastatic disease, including
in 45% pelvic and 18% extrapelvic lymph node metas-
tases. Treatment also included regional pelvic irradiation
with conventional fractionation. A total of 97% showed an
initial decrease in PSA levels after RT. Recurrent disease
was localized in 33 of 36 patients in a new PET/CT, 88%
outside of the initial RT field, with a median distant dis-
ease-free survival of 11 months. A shift in the pattern of
metastases towards more distant lymph nodes and skele-
tal involvement was reported. Recurrences after initially
treated pelvic lymph nodes occurred most frequently in
pelvic lymph nodes or the retroperitoneum [5].
Discussion
Currently available diagnostic methods, especially 68Ga-
PSMA PET/CT, allow the detection of oligometastatic or
oligorecurrent prostate cancer even at low PSA levels.
Research in metastasis-directed radiotherapy has recently
gained interest with the aim of improving survival outcomes
or deferring systemic treatment. To date, two prospective
randomized phase II studies and several cohort studies have
been published.
Two RT concepts are currently applied: SABR and
ENRT. In patients with lymph node metastases, many cen-
ters opted for focal SABR. Results supporting this approach
with excellent local control rates >85% have been pub-
lished by several groups [5, 13, 14]. Overall, a wide variety
of fractionation concepts are used, including conventional
fractionation for ENRT, moderate hypofractionation with
fraction doses of 2.5–3Gy, or ultra-hypofractionation with
fraction doses of 5–10Gy (common understanding of
SABR) [21]. In two prospective phase II randomized stud-
ies, improvements of progression-free survival, ADT-free
survival, and a decreased risk of new lesions were demon-
strated [13, 14]. Improved cancer-specific survival was
observed in a retrospective multi-institutional case–control
study after a longer median follow-up of 36 months [15].
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However, recurrence pattern analysis found a consider-
ably higher percentage of recurrences close to the irradi-
ated area following SABR in comparison to ENRT [5, 19,
20]. Thus, regional control rates and metastases-free sur-
vival could be improved with ENRT. Overall, comparative
studies suggest a prognostic advantage of ENRT in compar-
ison to SABR [16, 17]. In anatomical subregions containing
a single metastatic lymph node, the minimal short diameter
of tumor deposits required to reach a detection rate of 50
and 90% in 68Ga-PSMA PET/CT was estimated to be ≥2.3
and ≥4.5mm, respectively [22]. Following salvage lymph
node dissection, Jilg et al. [22] found the majority of false-
negative subregions (13/16) in regions neighboring true-
positive subregions.
In an analysis of 2694 patients treated with prostate
+/– seminal vesicle radiotherapy without nodal treatment,
156 patients had their first radiographically confirmed
(CT: 117; MRI: 27; PET/CT: 12) failure within the ab-
dominopelvic lymph nodes in the context of biochemical
failure [23]. Isolated failures within the pelvic nodes were
detected in 60 patients and the common iliac station was
involved in 55% (n= 33) of these patients. Extending the
field to cover the common iliac stations from L5/S1 to
L4/L5 would increase the coverage of first pelvic recur-
rences from 42 to 93%, supporting the results from De
Bruycker et al. [20].
ADT is accepted as a treatment modality in combination
with radiotherapy in primarily diagnosed prostate cancer
with regional lymph node metastases. Prospective random-
ized phase III data from Messing et al. [24, 25] found im-
proved overall survival rates in patients with positive lymph
nodes after radical prostatectomy and lymphadenectomy
who received immediate ADT (n= 47) in comparison to
deferred ADT (n= 51)—36 vs. 55% of patients died within
a median of 11.9 years follow-up. However, as this study
included only a small number of patients with a larger num-
ber of positive lymph nodes (median 2, range 1–20), ADT is
not generally accepted as a treatment for patients with lim-
ited lymph node involvement following lymphadenectomy
[7].
Patients who received salvage radiotherapy >15 years
ago, especially patients with higher PSA levels, would fre-
quently have been diagnosed with oligometastases with
current diagnostic methods. Prospective randomized stud-
ies demonstrated a benefit with the combination of salvage
radiotherapy and short-term (GETUG-AFU-16, 6 months,
improved 10-year progression-free survival of 64 vs. 49%;
p< 0.01) [26] or long-term (RTOG 9601, 24 months, sig-
nificantly improved overall survival for patients with pre-
salvage radiotherapy PSA 0.61–1.5ng/ml, HR 0.61; and
>1.5ng/ml, HR 0.45) [27, 28] ADT in patients with bio-
chemical recurrence (without PET/CT staging). For patients
with metachronous oligometastases in hormone-sensitive
prostate cancer, systemic treatment including ADT is the
standard of care [29]. However, this concept has recently
been challenged in prospective phase II studies, applying lo-
cal treatment to defer ADT. ADT is not regarded as standard
treatment for biochemical recurrence according to current
guidelines.
Importantly, local treatment has not yet been compared
with the standard of care. In the STOMP trial [13], crite-
ria for initiation of ADT were defined as “symptomatic
progression, progression to more than three metastases,
or local progression of baseline-detected metastases.” Pro-
gression by PSA increase alone was not an indication to
start ADT, nor was development of additional metastases
amenable to MDT as long as the patient still had three or
fewer total metastases. A retrospective multicenter study
of 305 PET-positive oligorecurrent prostate cancer patients
who received stereotactic or fractionated radiotherapy only
showed improved biochemical recurrence-free survival with
the addition of ADT for >6 months after a median follow
up of 16 months [30].
In patients with biochemical recurrence or asymptomatic
metastases, in particular with long PSA doubling times
>10 months and a longer relapse-free interval >2 years af-
ter initial curative treatment, ADT may be withheld initially
without compromising oncologic outcome [31]. For these
patients, deferred ADT has the advantage of maintaining
quality of life. Patient anxiety, compliance, comorbidities,
life-expectancy, and the toxicity of androgen deprivation
needs to be taken into account. Intermittent androgen de-
privation should be considered, as quality of life can be ex-
pected to be better in comparison to continuous androgen
deprivation [31]. Patients have to be assessed individually
in a multidisciplinary tumor board.
Molecular predictive factors might help to select patients
who will particularly benefit from MDT, such as patients
with an absence of high-risk mutations in ctDNA. In addi-
tion, the effect of radiotherapy on the immune system might
induce an in-situ vaccine response [14].
The results of randomized studies in patients with olig-
orecurrent nodal prostate cancer are eagerly awaited in the
next few years, such as the OLIGOPELVIS-2 trial compar-
ing ADT with ADT+ENRT, and the STORM trial (Salvage
Treatment of OligoRecurrent nodal prostate cancer Metas-
tases) comparing salvage lymph node dissection/SABR+
ADT with ENRT+ADT.
Conclusion and recommendations
Oligorecurrent prostate cancer is commonly diagnosed fol-
lowing PET/CT staging and defined as a locoregional or
distant recurrence in up to three (–five) locations.
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1. Oligorecurrent prostate cancer with lymph nodes limited
to the pelvis Conventionally fractionated elective pelvic
nodal radiotherapy with a boost to the involved nodes
(simultaneous integrated or sequential boost) should be
preferred over involved node SABR only, with lower recur-
rence rates and possibly improved cancer-specific survival.
Standard elective pelvic nodal radiotherapy includes the
obturator, presacral, internal, and external iliac lymph
nodes. Inclusion of common iliac lymph nodes is also
recommended.
2. Oligometastatic prostate cancer with distant nodal recur-
rences For nodal recurrences outside the pelvis, elective
nodal radiotherapy and SABR have not been sufficiently
studied. ENRT (specifically paraaortic nodes) or involved-
node SABR may be performed in selected cases.
3.Androgendeprivation therapy Systemic treatment should
be based on current guidelines, including long-term andro-
gen deprivation therapy as first-line treatment in hormone-
sensitive patients. In limited-volume disease, especially
if up to three lymph nodes are involved, local treatment
could be considered as upfront treatment in individually
selected patients, especially in patients with long PSA dou-
bling times >10 months and longer relapse-free interval
>2 years after initial curative treatment. However, this
concept has not yet been prospectively compared with the
current standard—radiotherapy combined with androgen
deprivation—and should therefore not be used routinely.
We recommend the inclusion of patients with oligore-
current prostate cancer in prospective clinical studies.
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